With a Covid-19 vaccine in hand, who should get it first? – STAT

he ethical challenges that have arisen so far in the coronavirus pandemic largely boil down to the age-old struggle between individual freedoms and the public good. Issues like restricting movement and commerce to protect community health or requiring health care workers to treat infected patients, even at the risk of getting infected themselves, are specific examples of this larger dilemma.

What needs to happen before we can all get vaccinated for COVID-19? | CBC News

COVID-19 has upended our lives, and we’ve all heard that there will be no return to “full normal” until there is a vaccine for the virus. But how close are we to a vaccine? What steps need to be taken? And how long will that take? Here’s a closer look.

The world may be overestimating the power of Covid-19 vaccines

ith a little luck and a lot of science, the world might in the not-too-distant future get vaccines against Covid-19. But those vaccines won’t necessarily prevent all or even most infections. In the public imagination, vaccines are often seen effectively as cure-alls, like inoculations against measles.

AstraZeneca could supply potential coronavirus vaccine from September

AstraZeneca has said it has the capacity to manufacture 1bn doses of the University of Oxford’s potential Covid-19 vaccine and will begin supply in September if clinical trials are successful. The Anglo-Swedish drugmaker said it had signed the first agreements to supply at least 400m doses of the potential vaccine, yet to be proven effective, which it is developing with the university.

Exclusive: A quarter of Americans are hesitant about a coronavirus vaccine – Reuters/Ipsos poll

(Reuters) – A quarter of Americans have little or no interest in taking a coronavirus vaccine, a Reuters/Ipsos poll published on Thursday found, with some voicing concern that the record pace at which vaccine candidates are being developed could compromise safety.

Vaccine experts say Moderna’s Covid-19 data leave big questions

eavy hearts soared Monday with news that Moderna’s Covid-19 vaccine candidate – the frontrunner in the American market – seemed to be generating an immune response in Phase 1 trial subjects. The company’s stock valuation also surged, hitting $29 billion, an astonishing feat for a company that currently sells zero products.

Coronavirus – Qué se sabe de la vacuna contra el coronavirus – RTVE.es

Casi al mismo tiempo que la pandemia de coronavirus comenzaba a traspasar fronteras como un tsunami imparable, laboratorios de todo el mundo iniciaban una carrera contra reloj para encontrar una vacuna que pueda contrarrestar al nuevo patógeno. No es el único recurso científico para detener al virus, pero sí el más importante.

Coronavirus, la virologa Ilaria Capua: “Non sarà il vaccino che ci porterà fuori da questo incubo”

La virologa Ilaria Capua ospite di Giovanni Floris a diMartedì

Safety concerns over vaccine for coronavirus still remain, says expert

Currently, more than 70 countries are participating in the World Health Organization (WHO)’s trial to accelerate research on effective treatments, and around 20 organizations are in the race to develop a vaccine, according to WHO Director-General Dr. Tedros Adhanom Ghebreyesus.

Can a century-old TB vaccine steel the immune system against the new coronavirus?

Researchers in four countries will soon start a clinical trial of an unorthodox approach to the new coronavirus. They will test whether a century-old vaccine against tuberculosis (TB), a bacterial disease, can rev up the human immune system in a broad way, allowing it to better fight the virus that causes COVID-19 and perhaps prevent infection with it altogether.